Invivyd authors evaluated early side effects of prior low-dose investigational monoclonal antibody adintrevimab from the EVADE study, ...

Invivyd authors evaluated early side effects of prior low-dose investigational monoclonal antibody adintrevimab from the EVADE study, demonstrating minimal tolerability issuesResults allow for compari ...

After the rofecoxib (Vioxx) withdrawal in 2004 made painfully clear how much harm a passive reporting system can miss, ...

Covid-19 vaccines roughly halved the chances that a US adult would need to visit the emergency room or be hospitalized with their infections last fall and winter, according to two sources familiar ...

Serious side-effects from vaccines were rare, scientists found in studies funded by US taxpayer money ...

Although COVID-19 vaccines have been shown to be highly effective in preventing severe illness, hospitalization, and death, information on the economic benefits of COVID-19 vaccination is lacking.

RSV and flu mRNA vaccines struggle with lower durability, higher side effects, and weak uptake, leading to program cuts and ...

Novavax posted Q1 revenue of $139.5 million, above analysts’ estimate of $78.3 million, helped by licensing agreements. ・The drugmaker also said that patients who received Nuvaxovid were “twice as ...

Jay Bhattacharya dismissed the test-negative design as 'crap.' The biostatistics literature tells a different story.